A great example of ACT efficacy against neoplastic disease is a therapy involving CD19 CAR-T cells in the treatment of relapsed or refractory B-ALL and relapsed or refractory diffuse large B-cell lymphoma in adult patients. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.